Bluejay Diagnostics closes $8.5M private placement with warrants for up to $23.7M total

Bluejay Diagnostics, Inc.

Closed private placement of 3,655,917 common shares (or pre-funded warrants) plus Series G and H warrants at $2.325/unit, raising $8.5M gross.
Net proceeds of ~$7.7M after placement agent fees; cash runway extended into Q1 2027, beyond expected FDA submission.
If all warrants exercised for cash, additional $15.2M proceeds would extend cash runway well beyond FDA approval and first year of commercialization.
Company must file resale registration statement by June 17, 2026 for underlying shares; warrants have exercise price $2.075.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Bluejay Diagnostics, Inc. issued pre-funded warrants to purchase up to 3,655,917 shares; Series G warrants to purchase up to 3,655,917 shares; Series H warrants to purchase up to 3,655,917 shar of warrant to institutional accredited investors for $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant.

Security: warrant
Shares: pre-funded warrants to purchase up to 3,655,917 shares; Series G warrants to purchase up to 3,655,917 shares; Series H warrants to purchase up to 3,655,917 shar
Purchaser: institutional accredited investors
Consideration: $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant

Exact text from the filing

and (iii) Series H warrants (the “Series H Warrants”) to purchase up to 3,655,917 shares of common stock. The combined price of securities sold in the private placement was $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant. The Pre-Funded Warrants are immediately exercisable for shares of common stock at an exercise price

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Bluejay Diagnostics, Inc. issued Placement Agent Warrants to purchase up to an aggregate of 255,915 shares of common stock of warrant to H.C. Wainwright & Co. for services as placement agent.

Security: warrant
Shares: Placement Agent Warrants to purchase up to an aggregate of 255,915 shares of common stock
Purchaser: H.C. Wainwright & Co.
Consideration: services as placement agent

Exact text from the filing

the Company issued to the placement agent (or its designees) warrants ("Placement Agent Warrants"

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Bluejay Diagnostics, Inc. entered into registration rights agreement with certain institutional, accredited investors (effective 2026-06-02).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional, accredited investors
Effective: 2026-06-02

Exact text from the filing

On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Bluejay Diagnostics, Inc. entered into securities purchase agreement with certain institutional, accredited investors valued at approximately $7.7 million (effective 2026-06-02).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional, accredited investors
Value: approximately $7.7 million
Effective: 2026-06-02

Exact text from the filing

On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”).

View on SEC.gov

114 equity issuances filed in the last 30 days. Browse all equity issuances →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-066364

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.